The Knowledge Hub for Medical Imaging Professionals: Transforming Radiology with Structured Reporting, Data-Driven Approaches and Multicentric Research

Access breakthrough research, innovative case studies and collaborative projects advancing radiology worldwide. Dive into our activities and product updates, and learn who we are as a company and as a team.

Screenshot of a prostate lesion in mint Lesion

Streamline Prostate Cancer Screenings with Prostate.Carcinoma.ai in mint Lesion

The Prostate.Carcinoma.ai plug-in, developed by our partner FUSE-AI, is a powerful addition to mint Lesion, designed specifically to enhance prostate cancer screenings. This advanced solution leverages artificial intelligence to automate and accelerate prostate MR evaluations based on the PI-RADS 2.1 guidelines, transforming the workflow and precision for radiologists.

At the click of a button, Prostate.Carcinoma.ai performs full segmentation of the prostate and its anatomical zones, and detects and segments potentially malignant lesions. mint Lesion maps each finding onto the standardized prostate lesion scheme, eliminating the need for time-consuming manual lesion annotation and drawing.

Radiologists maintain full control over the AI-generated results, with the ability to review, reject, modify, or add new findings to ensure accuracy. Based on these inputs, mint Lesion automatically calculates the PI-RADS score, delivering a comprehensive and structured report.

mint Lesion also enables longitudinal tracking of prostate lesions for MRI-based active surveillance. Radiologists can easily monitor changes in lesions over time, supporting informed decision-making for patient management and enhancing the continuity of care.

Learn more on our partner page.

Related Resources

Related Resources

A picture of workshop participants  next to a positive review for the ESOI-EORTC RECIST Workshop in Munich

ESOI-EORTC Workshop on Imaging in Assessing Response to Cancer Therapy - A Participant's Perspective

Following the conclusion of the ESOI-EORTC Workshop on Imaging in Assessing Response to Cancer Therapy in Munich, we were keen to gather feedback…

A diagram and a CT scan visualizing tumor growth rate in patients with refractory or relapsed lymphoma

Study with mint Lesion™ Uncovers the Impact of Tumor Growth Rate in Predicting the Efficacy of CAR-T-cell Therapy in Lymphoma Patients

A recent study conducted by Dr. med. Michael Winkelmann and his colleagues at the LMU Klinikum München explored the association between TGR dynamics…

Study Analyzing the Tumor Growth Rate as a Prognostic Biomarker in Lymphoma Patients Under CAR T-Cell Therapy

University Hospital Munich (LMU): Study Analyzing the Tumor Growth Rate as a Prognostic Biomarker in Lymphoma Patients Under CAR T-Cell Therapy

A recent study[1] conducted by researchers at the University Hospital Munich (LMU) investigated the role of tumor growth rate (TGR) in predicting the…